Summary
Edwards Lifesciences Corporation (EW) filed an 8-K report on October 19, 2011, to announce its financial results for the third quarter of 2011. The filing primarily directs investors to a press release (Exhibit 99.1) that contains the detailed financial performance for the period. This report serves as the official notification to the market regarding the company's operational and financial condition as of that date. While the 8-K itself is procedural, the attached press release is crucial for investors seeking to understand Edwards Lifesciences' performance, including revenue, profitability, and any significant operational developments during the third quarter of 2011. Investors should carefully review the press release for insights into the company's strategic execution and future outlook.
Key Highlights
- 1Edwards Lifesciences announced its third-quarter 2011 financial results on October 19, 2011.
- 2The 8-K filing serves as the official disclosure of these results.
- 3Detailed financial information is provided in an attached press release (Exhibit 99.1).
- 4The filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- 5The report indicates the company's principal executive offices are located in Irvine, California.
- 6Thomas M. Abate, Corporate Vice President and Chief Financial Officer, signed the report.
- 7This filing primarily serves to provide market participants with timely financial updates.